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ENGLISH SUMMARY 
Chronic pancreatitis (CP) is an inflammatory disease of the pancreas, manifested by 
abdominal pain, exocrine and endocrine insufficiency, and often leads to multiple 
hospitalizations leading to an immense burden on both patients and the clinicians. 
Particularly, treating chronic pain secondary to CP remains a difficult clinical problem 
to manage, as the current pain treatment is often unsatisfactory and accompanied with 
undesirable side effects. Hence, new specific treatments to control the CP pain are 
highly warranted. However, there are some difficulties in developing and trialing new 
treatments for CP pain i.e. the pathophysiology of CP pain is still incompletely 
understood.  
To date, several studies have demonstrated that the pain is largely driven by central 
mechanisms rather than morphological changes of the pancreas organ. Therefore, 
quantitative sensory testing and electroencephalography techniques have been used to 
identify changes of the central nervous system (CNS), however, the full extent of the 
CNS involvement in CP pain still remains largely unknown and needs to be 
investigated in more detail. The purpose of this Ph.D. project was to perform a 
multimodal magnetic resonance imaging (MRI) brain assessment of structural, 
functional and metabolic properties to provide more objective information about the 
role of the CNS in the pathophysiology of chronic pain in CP. 
Four papers compile this Ph.D. project. Paper I was based on a longitudinal study, 
assessing the brain morphology changes using structural MRI. This study 
demonstrated predominantly reduced gray matter volume and cortical thinning in pain 
related areas over a 7-year follow up period. Furthermore, gray matter volume loss in 
the thalamus was associated with pain scores.  
The remaining papers (II, III and IV) were based on a cross-sectional study. Paper II 
aimed to assess the brain morphology in CP patients as well as identifying the most 
prominent risk factor associated with altered brain structure. This study confirmed 
that CP patients had reduced gray matter volume and cortical thinning. Interestingly, 
this study found that alcoholic etiology of CP is the most prominent factor associated 
with gray matter volume loss. Overall, Paper I and II provide evidence of structural 
reorganization of the brain in CP patients. Paper III used MR spectroscopy to assess 
brain metabolites changes in CP patients. This study showed that CP patients had 
increased glutamate/creatine level in the anterior cingulate cortex (ACC) and was 
associated with patients’ pain symptoms. Additionally, Paper III revealed that patients 
with alcoholic etiology of CP had reduced N-acetyl-aspartate/creatine level, compared 
with CP patients without alcoholic etiology. Finally, Paper IV assessed functional 
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connectivity alterations in two brain networks (default mode and salience network). 
Paper IV showed that CP patients had hyper-connectivity in both networks. 
Furthermore, the communication between those networks were disrupted, given that 
the anti-correlation was reduced in CP patients compared with healthy controls. Most 
interestingly, Paper IV showed an association between altered ACC glutamate level 
in CP patients and altered default mode network, implicating that glutamate may 
modulate the function of the default mode network. Overall, Paper IV provides strong 
evidence of functional reorganization of the brain in CP patients.  
This multimodal MRI study provides strong evidence of structural and functional 
reorganization in CP patients, in addition to metabolic brain alterations. Taken 
together, these brain alterations may arise from a combination of both sustained 
nociceptive effect of long-lasting pain and previous neurotoxic effect of alcohol. This 
knowledge contributes to improve insight into pain mechanisms and treatment in CP, 
suggesting that the treatment must also be aimed at the CNS. The first step in treating 
pain could be examination and profiling the sensory system in CP patients, enabling 
the clinicians to provide a more precise and effective (personalized) treatment based 
on the central pain mechanisms.  
Additionally, this Ph.D. thesis also provides valuable knowledge to design future 
clinical studies with painful CP patients.  
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DANSK RESUME 
Kronisk pancreatitis (KP) er en kronisk betændelsestilstand af bugspytkirtlen 
(pankreas) og er en relativ hyppig årsag til kroniske mavesmerter, der medfører 
betydelige personlige, samfundsmæssige og økonomiske problemer. KP er 
karakteriseret ved progressiv ødelæggelse af pankreas med atrofi, bindevævsdannelse, 
eksokrin insufficiens og endokrin insufficiens.  
Kroniske mavesmerter er det vigtigste symptom hos KP patienter. Traditionel 
smertebehandling med morfinlignende lægemidler har ofte en begrænset og 
utilstrækkelig effekt på smerterne og har tit uønskede bivirkninger. Derfor er nye 
behandlingstiltag nødvendige. Tidligere har KP smertefysiologien fokuseret på selve 
pankreas organet, hvor man mente at anatomiske forandringer i pankreas medførte 
smerte, men nyere studier har vist, at der ikke er nogen klar sammenhæng mellem 
anatomiske forandringer i pankreas og smerterne. Samtidigt har man vist, at smerte 
ved KP involverer sensibilisering af centralnervesystemet med øget følsomhed for 
sensorisk påvirkning. Dette spiller en vigtig rolle i udviklingen af de kroniske smerter.  
Den seneste udvikling indenfor radiologien har muliggjort kortlægning af hjernens 
struktur og funktioner med avancerede magnetisk resonans (MR) billeddannelse. 
Dette ph.d.-projekt har til formål at undersøge I) strukturelle, II) metaboliske og III) 
funktionelle hjerneforandringer hos patienter med KP sammenlignet med raske 
forsøgspersoner. Projektet indeholder to studier: Et longitudinelt studie og et 
tværsnitsstudie, som resulterede i fire videnskabelige artikler.  
Artikel 1 undersøgte udviklingen af strukturelle MR hjerneforandringer over en 
periode på 7 år hos KP patienter. Denne artikel viste, at patienterne havde reduceret 
volumen af grå substans og nedsat tykkelse hjernebarken i smerte relaterede områder 
i hjernen som hænger sammen med udviklingen af smerterne.  
Artikel 2 undersøgte strukturelle MR hjerneforandringer med henblik på at 
identificere de mest betydende risikofaktorer, som driver morfologiske 
hjerneforandringer hos patienter med KP. Denne artikel, bekræftede reduceret 
volumen af grå substans og nedsat tykkelse af hjernebarken. Endvidere, blev tidlige 
brug af alkohol (alkoholisk ætiologi for KP) identificeret som den mest betydende 
risikofaktor relateret til morfologiske hjerneforandringer hos KP patienter.  
Artikel 3 undersøgte metaboliske forandringer i hjernen med MR spektroskopi. Dette 
studie viste, at patienterne har øget glutamat/kreatine koncentration i hjerneområdet 
anterior cingulate cortex (ACC). Patienterne med mest smerte havde ligeledes højst 
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glutamat/kreatine koncentration. Ydermere viste artikel 3, at patienterne havde 
signifikant reduceret N-acetyl-aspartat/kreatin koncentration i det parietale område i 
hjernen, som ligeledes var associeret til tidlige brug af alkohol.  
Artikel 4 undersøgte hjernens funktionelle netværk hos patienter med KP og viste, at 
patienterne havde øget konnektivitet i to vigtige netværk (default mode og salience 
netværkene). Patienterne havde ydermere reduceret anti-korrelation mellem 
netværkene, hvilket indikerer en ubalance i kommunikation i hjernen hos patienter 
med KP, som også ses hos andre patienter med kroniske smerter. Afslutningsvis, viste 
artikel 4 en sammenhæng mellem forstyrret konnektivitet i default mode netværket 
og glutamat i ACC.  
Den overordnede konklusion i dette ph.d. projekt er, at patienter med KP har både 
strukturelle, metaboliske og funktionelle hjerneforandringer, som tyder på at være 
drevet af både smerte og neurotoksisk effekt (tidligere alkohol misbrug). Idet, dette 
ph.d. projekt har påvist, at KP patienter har udtalte hjerneforandringer, bør fremtidige 
behandlinger være CNS målrettet og selve behandlingen bør tilrettelægges efter den 
enkelte patients karakteristika ved eksempelvis at fænotype patienternes sensoriske 
smerte system.  
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CHAPTER 1. INTRODUCTION 
 
Chronic pancreatitis (CP) is a progressive fibro-inflammatory disease of the pancreas 
and is a major source of morbidity with a prevalence of CP, varying between 120 and 
140 per 100,000 population (1). CP has an essential clinical and economic impact, and 
the pain in CP represents the main challenge for primary care physicians and 
gastroenterologists (2).   
Abdominal pain is the primary clinical manifestation in CP patients associated with a 
negative impact on the overall quality of life (QoL) (3). The pain mechanisms are 
incompletely understood and probably multifactorial, which often results in 
insufficient and empirical treatment. Previously, the understanding of pain in CP has 
been focused on the pancreas, assuming pain is caused by increased parenchymal or 
ductal pressure. However, there is a growing evidence that alterations of the central 
nervous system (CNS) also play an important role in the pathophysiology and 
symptom generation (4,5).  
Thus far, quantitative sensory testing (QST) studies and electroencephalography 
(EEG) studies have made major progress in identifying key neural structures within 
the brain-gut axis involved in CP (5). Particularly, QST studies have shown that pain 
in CP and other visceral pain syndromes share similarities in pain mechanisms, with 
evidence of both peripheral and central sensitization (6). Moreover, EEG studies have 
demonstrated following characteristics in CP patients: 1) functional reorganization of 
the insular cortex, 2) thalamocortical dysrhythmia, and 3) cortical hyperexcitability 
(5,7). However, the full extent of the CNS involvement in CP pain still remains largely 
unknown and needs to be investigated in more detail to improve our understanding of 
the pain mechanisms in CP and potentially improve the pain treatment.  
In addition to EEG, magnetic resonance imaging (MRI) is another valuable 
neuroimaging technique to study the brain non-invasively. Comparing to EEG, MRI 
has an excellent spatial resolution, specifically in the superficial layers of the brain 
(8). Hitherto only few MRI studies have investigated the CNS in CP patients (9,10), 
reporting that CP patients have cortical thinning in brain areas involved in pain 
processing (9), as well as microstructural white matter changes (11). Although, these 
studies have contributed to our knowledge of the brain structure in CP patients, they 
have some limitations i.e. only few pre-selected areas of the brain were investigated. 
Hence, there is a need to study the whole brain anatomy thoroughly in CP patients.  
20
 
MRI can provide important structural features such as brain volumetry (i.e. gray 
matter volume), and cortical thickness (12). Furthermore, MRI provides functional 
characteristics of the brain using blood-oxygen-level dependent (BOLD) signal. This 
approach is the most widely used technique in functional MRI (fMRI) (13). 
Additionally, neurochemical activities, i.e. concentration of neurotransmitters, can be 
assessed using MR spectroscopy (14). Characterization of the structural, metabolic 
and functional brain with multimodal MRI modalities, will greatly improve our 
understanding of CP pathophysiology.   
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CHAPTER 2. BACKGROUND 
2.1 CHRONIC PANCREATITIS: PATHOPHYSIOLOGY, 
ETIOLOGY AND SYMPTOMS 
 
Chronic pancreatitis is a multifactorial disease, seen in both males and females, 
however it is more common in men with a gender ratio (male/female) of 4.6 (15). The 
prevalence of the disease increases with age (15), and moreover CP has been shown 
to be associated with approximately 50% mortality rate within twenty years of 
diagnosis (16).    
Acute pancreatic, recurrent acute pancreatitis, and CP are interconnected in a disease 
continuum and share some common features i.e. progressive inflammation of the 
pancreas (17,18). Acute pancreatitis is characterized by acute and partly reversible 
pancreatic injury, whereas CP is characterized by irreversible pancreatic injury 
resulting in loss of pancreatic parenchyma and functions (19). It is widely 
acknowledged that CP is the end result of repeated attacks of acute pancreatitis and 
chronic inflammation, leading to clinical manifestations such as exocrine and 
endocrine insufficiencies (18).  
During the last couples of years, several hypothesis have been proposed explaining 
the pathophysiology of the CP. At the moment, sentinel acute pancreatitis event 
(SAPE) hypothesis model (18) is the most prevailing hypothesis proposed to be 
involved in the development of CP (16,20). SAPE-model, contains several elements 
such as 1) the necrosis-fibrosis hypothesis, 2) the toxic-metabolic hypothesis, and 3) 
the oxidative stress hypothesis (21).  
In general, SAPE model is based on a “two-hit” hypothesis and can be divided into 
three stages (Figure 1) (21). The first stage is called, pre-acute pancreatitis stage, in 
which the risk factors (genetic, metabolic and environmental) will be recognized, and 
then a first (sentinel) episode of acute pancreatitis activates the immune system 
(including proinflammatory and anti-inflammatory response) (18,21). The latter is the 
second stage, named the initial attack of acute pancreatitis stage, which is also 
considered as the “first hit” (18,21). The outcome of acute pancreatitis can either be 
complete recovery, or pathologically progression towards CP, which is the third stage, 
called progression stage (18,21). The third stage is highly dependent on factors that 
drive the immune system, thru several stressors (alcohol, smoking) and remains the 
“second hit” (Figure 1) (21). For example, patients with minimal ongoing stress to the 
immune system and no major changes to the immune system, appears to return to 
normal pancreas, already after the first attack of acute pancreatitis and becomes 
completely recovered. In contrast, patients with continued stress to the immune 
22
 
system (i.e. alcohol/smoking), progress towards CP (21).  The pathological 
progression towards CP may be triggered by several mechanisms i.e. oxidative stress, 
progressive inflammation, or repeated episodes of acute inflammation, which may or 
may not be clinically apparent (18,21,22).  
 
Figure 1: Overview of the sentinel acute pancreatitis event hypothesis. This hypothesis 
proposes that an initial episode of acute pancreatitis sensitizes the pancreas and is the very 
first step in a series of events resulting in CP. Abbreviations:  CP: Chronic pancreatitis. SAPE: 
sentinel acute pancreatitis event. 
To date several classification systems of the etiology behind CP exist, i.e. The 
American classification system, TIGAR-O, is based on various risk factors, and can 
be categorized into six groups (1) Toxic-metabolic, (2) Idiopathic, (3) Genetic, (4) 
Autoimmune, (5) Recurrent and severe acute pancreatitis or (6) Obstructive (15).  
The European classification system,  M-ANNHEIM, is another widely used 
classification system, describing the heterogeneity of the pathology in detail based on 
etiological risk factors such as: alcohol consumption, nutritional factors, hereditary 
factors, efferent duct factors, immunological factors and miscellaneous including 
metabolic factors (23). Additionally, M-ANNHEIM classification enables to classify 
the patients according to clinical stage, and severity of the CP disease (24). Even 
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though, the TIGAR-O and M-ANNHEIM classifications are two different 
classification system, they share same features and overlap greatly. 
In Western countries, it is generally accepted that excessive consumption of alcohol 
over many years, is the most common cause for developing CP. Current literature 
suggests that  approximately half of the patients have alcoholic etiology (3,16). 
Together with alcohol, smoking remains a common co-existing risk factor, 
contributing to the development of CP. Smoking does not only increase the risk factor 
for CP, but does also increase the risk factor for pancreas cancer (16).    
The most significant clinical symptom in CP is abdominal pain, presenting up to 90% 
of patients and pain is the primary cause for patients seeking medical care (3). 
Furthermore, chronic abdominal pain causes impairment of QoL, disability and 
unemployment resulting in major healthcare costs (3,25,26). CP pain often originates 
in the epigastrium and radiates to the back in a belt-like manner and is highly 
fluctuating (27). Furthermore, the pain may often manifests as postprandial pain, 
associated with nausea and vomiting. The pain pattern in CP patients can be divided 
into three groups: A) Intermittent pain, B) constant pain, and C) constant pain with 
acute exacerbations (28). The causes of pain have previously been explained by 
structural changes of the pancreas and increased pressure in the ductal system or tissue 
(25,29). However, in cases of more long-lasting pain, alterations of the CNS have also 
been found to play a role, indicating that the chronic pain in CP probably also has a 
neuropathic origin (19). Among other, chronic visceral pain is considered to be the 
most severe complication of CP, mainly as it is poorly understood and challenging to 
treat (3). In addition to pain, CP is often accompanied by other symptoms arising from 
the autonomic and enteric nervous system that may need specific management, 
including exocrine and endocrine insufficiency accompanied with weight loss, 
steatorrhea,  and other gastrointestinal disturbances (30).  
Currently, analgesics are the cornerstone of CP pain management, but when opioids 
are used, it may consequently result in dependency, opioid-induced hyperalgesia and 
other side-effects such as opioid-induced constipation, and cognitive dysfunction (31). 
Most despondently, CP patients are treated with opioids, despite the lack of clear 
evidence that they are effective for long-term pain management (31). Finally, if the 
analgesic therapy fails, invasive treatments including endoscopic pancreatic duct 
clearance, stenting, and surgery can be considered. However, invasive treatments are 
not always effective for pain relief, probably reflecting that many CP patients suffer 
from chronic visceral pain which may likely be due to abnormal central pain 
processing (31).  
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2.2 PHYSIOLOGICAL PAIN PROCESSING 
 
According to Woolf et al (32), pain can be classified into 1) nociceptive pain (the 
physiological protective system), 2) inflammatory pain (tissue damage), and 3) 
pathological pain (abnormal functioning of the nervous system). In order to 
understand the pathological pain in patients with CP, we first need to understand the 
physiologic pain. Therefore a brief section of pain physiology will be addressed.  
According to the International Association for the Study of Pain (IASP), pain is 
defined as “an unpleasant sensory and emotional experience associated with actual 
or potential tissue damage in terms of such damage”, indicating that pain has 
objective, physiological sensory components in addition to subjective emotional and 
psychological components (33). Although pain is associated with unpleasantness and 
negative thoughts, it is an indispensable mechanism for the human body, preventing 
and minimizing tissue damage from the environment, using the neural mechanisms 
for pain and nociception (34).  
Pain physiology (nociception) involves four neural processes; A) transduction, B) 
transmission, C) modulation and D) perception (Figure 2) (35).  
The transduction refers to the process that turns the noxious stimulus (mechanical, 
thermal or chemical) into electrical signal by nociceptors (free afferent nerve ending) 
(36). Then, transmission is the second step, in which the nociceptive information is 
transmitted from the peripheral nervous system to the CNS in several phases: 1) from 
periphery to spinal cord and 2) from spinal cord to the brain (36). From the periphery, 
the nociceptive inputs travel to the dorsal horn of the spinal cord. Here, excitatory 
neuropeptides i.e. glutamate is capable to facilitate and amplify the pain signals, while 
inhibitory amino acids i.e. GABA and neuropeptides reduce the nociceptive response 
through descending inhibitory system (36,37). These processes are covered by 
modulation and occurs at several levels i.e. peripheral, spinal, and supraspinal level. 
Thus, modulation takes place simultaneously, so the brain can alter the transmission 
of a nociceptive signal (36–38). Phase two in transmission (from spinal cord to the 
brain), projects the nerve processes of the dorsal horn to the brain in bundles termed 
ascending tract, transmitting the nociceptive inputs to the thalamus through 
spinothalamic tract and is further processed to the somatosensory cortex (36). Finally, 
perception is the cerebral cortical response to the nociceptive signals involving the 
limbic system. Perception includes several processes i.e. attention, expectation, 
emotions, and interpretation (35,36).  
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These four steps of the pain pathway are the fundamental basis for the nociceptive 
signaling and processing. The above four neural processes can be assessed using 
methods i.e. QST (33). QST provides clinicians and researchers the opportunity to 
investigate abnormalities in the sensory system as well as characterizing mechanisms 
underlying pathological pain disorders (25). 
 
Figure 2: Conceptual model for pain mechanisms involved in chronic visceral pain. 
Nociceptive pathway consists: A) Transduction, B) Transmission, C) Modulation, and D) 
Perception. Examples of altered pain mechanisms in CP: central sensitization (incl. 
hyperalgesia and allodynia), cortical reorganization in the brain and defect in descending pain 
pathways.  
 
2.3 PATHOLOGICAL PAIN IN PATIENTS WITH CHRONIC 
PANCREATITIS 
 
Pain originated from visceral organs (i.e. heart, lungs, gastrointestinal tract, pancreas 
etc.), is called visceral pain, whereas pain arising from tissues such as skin, muscle, 
join capsules and bone is called somatic pain (39). Although visceral pain, as seen in 
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CP patients, share some mechanisms with somatic pain, there are some major 
differences in central nociceptive processing of pain (40),  that should be considered 
when initiating analgesic treatment (33,41). For instance, visceral pain is described as 
diffuse and difficult to localize (30,42).  
For many years, the CP pain theories were focused on the pancreatic gland, and it was 
believed that the pain in most patients was caused by anatomical changes such as 
increased ductal and intestinal pressure (29). This was the basis for the mechanistic 
understanding of pain, called “the plumbing theory” and is the rationale for most 
interventions i.e. surgical and endoscopic procedures. However, recent studies have 
provided evidence of no association between microstructural and macrostructural 
findings and the pain characteristics (43,44). Currently, the literature suggest that the 
peripheral and central pain processing is abnormal in CP patients, mimicking 
neuropathic pain disorders (3,45). Particularly, studies have provided evidence of 
pancreatic neuropathy and neuroplasticity at the peripheral level and at the central 
level of the sensory system (3).   
The mechanisms that involve peripheral nervous system can be grouped into 
morphological and functional changes (46). Among others, morphological changes 
include enlarged neural density, neural hypertrophy and pancreatic neuritis. 
Functional changes include reduced sympathetic innervation.  
 
The mechanisms that involve changes in the CNS are central sensitization, impaired 
pain modulation, as well as cortical reorganization and hyperexcitability (46). 
Normally, central pain processing is balanced between descending excitatory and 
inhibitory drives, however in CP patients, it has been observed that an imbalance 
between inhibitory and facilitatory descending pain modulatory systems occurs, 
resulting in greater gain of incoming nociceptive signals (19,46).  
Sensitization in CP is characterized by hyperalgesia (an increase in responsiveness 
and prolonged aftereffect to noxious stimuli) and allodynia (a reduction in pain 
thresholds with pain in response to stimuli which normally does not induce pain) (33). 
The hyperalgesia can manifest either locally as seen in peripheral sensitization or 
generalized as observed in central widespread sensitization (Figure 2) (3).  
 
Cortical reorganization has been demonstrated in CP patients with chronic visceral 
pain using EEG studies, and hyperalgesia has been observed to be associated with a 
functional reorganization of the cerebral cortex (5). Particularly, it has been shown 
that CP patients show reorganization of brain areas involved in visceral pain 
processing including the insula, secondary somatosensory cortex and cingulate cortex 
compared to healthy controls (7,9). The patients had not only reorganization of the 
brain in the visceral pain processing regions, but showed also abnormal excitability 
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of these neural networks, reflecting cortical neuronal hyper-excitability (25). Another 
major finding from previous EEG studies is that disturbance of the thalamo-cortical 
interplay has been observed in CP patients with pain (5). Also, structural cortical 
reorganization has been demonstrated in CP patients using MRI techniques (9,11). 
Particularly, microstructural white matter changes in the insular and frontal brain 
areas as well as cortical thinning were found in CP patients (9,10). To date, 
neuroimaging studies have made a major contribution in understanding the pain 
related alterations occurring in CNS in general (47,48). However, there still is a 
knowledge gap regarding the involvement of the CNS in CP patient with chronic 
visceral pain. Particularly, it is unknown whether the gray matter volume is affected 
by the CP disease, and how clinical manifestations are related to brain changes over 
time, as well as, which factors drive the alterations in the CNS. In attempt to address 
the above mentioned knowledge gaps, this Ph.D. study uses advanced multimodal 
MRI assessments to assess the CNS changes in CP patients.  
 
2.4 ASSESSMENT OF CHANGES IN THE CNS WITH 
NEUROIMAGING TECHNIQUES 
  
The majority of the information we have regarding brain anatomy came from the study 
of thin histological sections that have been stained to show nerve cells and their 
process. However, during the last decades, a new generation of non-invasive imaging 
techniques has allowed us to in-vivo study the anatomy, physiology and 
pathophysiology in the human brain (8).  
Neuroimaging techniques can be grouped into following categories (8,14): 
 Functional neuroimaging: Functional MRI, magnetocencephalography (MEG), 
and EEG 
 Structural imaging: MRI 
 Biochemical neuroimaging: MR spectroscopy and positron emission tomography 
(PET)  
 
This Ph.D. project will only focus on functional MRI, structural MRI and MR 
spectroscopy.  
Functional MRI typically measures the BOLD signal based on the consumption of 
oxygen, induced by the neuronal activity. More precisely the fundamental basis of the 
BOLD signal relies on the magnetic properties of hemoglobin (Hb) (49). Hb is the 
protein molecule in red blood cells, carrying the oxygen and exists in two different 
forms, each with different magnetic properties (49). When the Hb is carrying the 
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oxygen, the Hb is in an oxygenated form (oxy-Hb) and has diamagnetic properties. In 
contrast, when the Hb is not carrying the oxygen, the Hb is in a deoxygenated form 
(deoxy-Hb) and has paramagnetic properties (49). Due to the different magnetic 
properties of Hb, different local magnetic fields are generated, i.e. deoxy-Hb 
suppresses the MR-signal because of its paramagnetic properties. Hence, as the 
concentration of deoxy-Hb decreased, the fMRI signal increases (49). Overall, 
changes in the ratio of oxygentated and deoxygentated blood can be inferred with 
fMRI by measuring the BOLD response. However it is important to note that the, 
BOLD signal is not directly measuring the neuronal activity, instead it measures the 
metabolic demands (oxygen consumption) of active neurons (49,50). 
Structural neuroimaging enables to macroscopically study gray matter volume (voxel-
based morphometry, VBM), cortical thickness (surface-based morphometry, SBM), 
fiber integrity (diffusion tensor imaging, DTI), and fiber tract density (tractography), 
which can reveal information on neuroplastic reorganization of the brain (48,51). MR 
spectroscopy remains another powerful tool providing biochemical information of the 
brain, including brain metabolites e.g. glutamate, N-acetyl aspartate, etc. (52).  
With combination of three different MRI techniques, enormous knowledge of pain 
processing in the brain can be achieved, and furthermore, a profound understanding 
of pain mechanisms can be obtained to enhance clinical intervention as well as 
improve pain treatment. 
2.5 REPRESENTATION OF PAIN IN THE BRAIN 
 
MRI studies have improved our understanding of how the brain alters in patients with 
chronic pain or responds to pharmacological treatments (53–55) by  providing novel 
information into structural, functional and neurochemical changes in several chronic 
pain conditions (56). Across multiple chronic pain conditions, structural changes in 
gray matter volume, and white matter volume have been demonstrated, indicating 
chronic pain to be a neurodegenerative disease (47). Furthermore, fMRI studies have 
shown that insular, anterior cingulate cortex, primary sensory cortex, thalamus and 
prefrontal cortex, and dorsolateral prefrontal cortex (DLPFC) are the most 
consistently activated brain regions functionally related to pain processing (47,48). 
Finally, MR spectroscopy studies have shown changes in neurotransmitters in chronic 
pain patients, by identifying neuronal and axonal markers, including glutamate, 
asparate, glycine, and GABA (47). Despite the enormous neuroimaging research in 
chronic pain, only limited research have been conducted on pain in CP patients using 
EEG and MRI. Although EEG is a valuable neuroimaging technique, it has some 
weakness i.e. poor spatial resolution. With MRI it is possible to non-invasively assess 
the brain with good spatial resolution and relatively good temporal resolution (51).   
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CHAPTER 3. HYPOTHESES & AIMS 
 
The overall aim of this Ph.D. thesis was to perform multimodal MRI brain assessment 
of structural, functional and metabolic properties to provide objective information 
about the role of the CNS in the pathophysiology of chronic pain in CP. This 
knowledge could contribute to improve insight into pain treatment in CP. Thus, we 
hypothesized that structural, metabolic and functional alterations of the brain are 
present in patients with CP and that those alterations were associated with the disease 
characteristics (including risk factors and clinical outcomes i.e. chronic pain). Taken 
together, a multimodal objective assessment approach would likely provide 
complementary information in understanding the complex pain mechanisms in these 
patients. The thesis is based on three peer-reviewed papers and an additional paper, 
which is under review.  Those four papers are compiling data from two studies; a 
longitudinal study (study I) and a cross-sectional study (study II). The four papers will 
from hereon be referred to as indicated in Figure 3.  
 
Subsequently, to fulfill the overall aim, the thesis contains following 3 aims: 
 Aim I: To investigate changes in the brain structure over time using structural 
MRI in painful CP patients compared with controls (Paper I) and potential 
associations to pain related symptoms (Paper I) and to explore associations 
between morphological brain changes and disease characteristics and risk factors 
(Paper II). 
 
The hypothesis was that CP patients, in comparison to healthy controls, had a) 
progression of reduced gray matter volume and cortical thickness in areas 
involved in visceral pain processing, and b) that brain changes were associated 
with the disease characteristics including pain, and risk factors for CP. 
 
 Aim II: To assess brain metabolites using MR spectroscopy in CP patients, 
compared with healthy controls, in pain related areas (ACC, insula and prefrontal 
cortex) and in a parietal control region, as well as to compare brain metabolite 
levels in subgroups with different disease characteristics including pain (Paper 
III). 
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The hypothesis was that CP patients had increased glutamate levels in pain 
related brain areas and that metabolites changes were associated to disease 
characteristics and patient outcomes.  
 
 Aim III: To assess the resting state networks (default mode and salience mode 
networks) using functional MRI in CP patients compared with healthy controls, 
and to explore the association between altered brain network connectivity and the 
clinical parameters as well as brain metabolites (Paper IV).  
 
The hypothesis was that the CP patients demonstrated reduced anti-correlation 
between default mode network and salience network connectivity compared to 
healthy controls, and that the altered brain connectivity was associated to the 
pain related clinical parameters and levels of brain metabolites.  
 
 
Figure 3: Overview of MRI modalities used in different aims which are investigated in study I 
and study II, presented in papers I-IV. Chronic pancreatitis patients and healthy controls were 
included in both studies. Abbreviations: MRI: magnetic resonance imaging.  
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CHAPTER 4. MATERIALS AND 
METHODS 
 
4.1 MATERIALS 
 
This Ph.D. thesis is based on two MRI studies conducted at the Departments of 
Radiology and Gastroenterology, Aalborg University Hospital: 1) a longitudinal study 
(study I) (presented in Paper I) and 2) a cross-sectional study (study II) (presented in 
Papers II+III+IV). Both studies were approved by the Ethics of Committee of 
Northern Jutland. For the longitudinal study the reference numbers were: N-
20080028MCH and N-20090008. For the cross-sectional study, the reference number 
were: N-20090008, N-20130040, and N-20170023. Both studies were carried out in 
accordance to the Declaration of Helsinki. Screening sessions and physical 
examinations were conducted at the Department of Radiology, Aalborg University 
Hospital. The screening and the inclusion of the patients were performed by a medical 
doctor according to the Research Ethics Committee’s guidelines. In order to 
participate in the respective studies, patients fulfilled the inclusion/exclusion criteria. 
The inclusion/exclusion criteria were identical for both studies. The inclusion criteria 
were as follows: (1) patients from the age of 18 years with a diagnosis of CP using the 
Mayo Clinic diagnostic criteria (57), (2) either chronic abdominal pain lasting for 
more than 3 days per week for the last 3 months or CP patients without ongoing pain, 
and (3) stable pain medication, including opioids/non-opioids. The exclusion criteria 
were as follows: (1) incapability to undergo MRI, (2) major illness i.e. cancer, (3) 
patients must not suffer from significant painful conditions other than CP, which make 
them unable to distinguish the pain related with CP from pain in other regions, (4) 
continuous and ongoing alcohol or drug abuse, and (5) had previously diagnosed 
depression or other significant mental illness.  
For both studies, healthy controls were age and sex matched with the CP patients. 
Healthy controls had no previous history of chronic pain conditions nor 
gastrointestinal disease. Additionally, they were allowed to take their ordinary 
medication i.e. blood pressure medication. However, they were excluded if they used 
CNS active medication.  
4.2 STUDY I 
  
Study I was a 7-year prospective study consisting of CP patients and healthy controls. 
Both groups were seen on two visits: A baseline visit, which took place from 2009 to 
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2010 and a 7-year follow-up visit which took place from 2016 to 2017. Twenty-three 
CP patients and 14 healthy controls participated in the baseline visit, while only 11 
CP patients and 12 healthy controls continued the study and completed the follow-up 
visit. At both visits, all participants underwent a single MRI scan session consisting 
of a high-resolution T1-weighted anatomical scan using exactly the same 3T MRI 
scanner. Furthermore, diffusion tensor image (DTI) was also acquired, however these 
data were not included in the Ph.D. study. Additionally, all patients fulfilled the BPI 
questionnaires and pain diary, and clinical characteristics were obtained from the 
patient medical records.  
 
4.3 STUDY II 
 
Study II was a cross-sectional study with 35 CP patients and 23 healthy controls. All 
participants underwent a single scan session consisting of a high-resolution 3D T1-
weighted anatomical scan, resting state fMRI scan, and MR spectroscopy. In addition, 
DTI was also acquired, however these data were not included in the Ph.D. study. 
Patients also fulfilled QoL questionnaire, BPI questionnaires, and furthermore clinical 
characteristics were obtained from the patient medical record.  
4.4 METHODS  
 
As outlined above, both subjective and objective techniques were used in study I and 
study II (Table 1). Subjective techniques utilized in both studies were pain diary, BPI 
questionnaire, and QoL questionnaires. Those questionnaires were used to assess the 
subjective experience of pain perception as well as the health-related QoL in CP 
patients. A standardized pain scale called numeric rating scale (NRS) was used in the 
pain diary. Multimodal MRI techniques were used for objective brain assessment. 
Particularly, structural MRI, fMRI and proton MR spectroscopy were used to assess 
the brain changes. Both subjective and objective techniques are described in details in 
the following sections.  
Subjective assessments Objective assessments 
- Pain diary (study I)  
- BPI questionnaire (study I+II) 
- Quality of life questionnaire 
(study II) 
- 3D T1-weighted anatomical scan 
(study I and II) 
- MRI spectroscopy (study II) 
- Functional MRI (study II) 
Table 1. Overview of methods used in study I, and study II. Abbreviations: BPI: brief pain 
inventory. MRI: Magnetic resonance imaging.  
 
33 
4.4.1 SUBJECTIVE ASSESSMENTS 
 
In study I, CP patients were asked to complete the pain diary one week prior to MRI 
scan, both at the baseline and follow-up visits. Pain diary consisted to two questions. 
First, the average of the patients’ level of pain during the respective day and second, 
the maximum intensity of the patient’s level of pain during that day were asked. For 
this purpose a NRS for pain was used, which is a scale of 0 (no pain) and 10 (worst 
pain imaginable). Among others, NRS is one of the most commonly used rating scales 
for assessing pain and has an excellent test-retest reliability (58). NRS has been 
validated in patients in rheumatic and other chronic pain condition, and is widely used 
in the clinic and CP research (59,60).  
BPI questionnaire was used to assess the clinical pain in CP patients in both study I 
and study II. The BPI questionnaire assesses pain at its “worst”, “least”, “average” 
level/intensity during the last 24 hours and “now”. Based on the four items, the 
average BPI pain score was calculated. Moreover, the BPI questionnaire assesses to 
which degree the pain has interfered with daily lives. Based on seven interference 
items, the average BPI interference was calculated (61). The BPI questionnaire has 
been validated in several pain conditions such as cancer pain, fibromyalgia, and 
neuropathic pain (61). Even though BPI questionnaire has not been validated in CP 
patients, it is commonly used in CP research (62).  
In study II, the European Organization for Research and Treatment of Cancer Quality 
of Life Questionnaire Core 30 (EORTC-QLQ-C3O) was used to assess the health 
related QoL. Quality of life questionnaire is validated in several chronic pain 
conditions (63), and is widely used in CP patients (28). Recently a study evaluated 
QoL in CP patients, recommending to use QoL questionnaire to evaluate the well-
being of CP patients (64). This questionnaire contains three main domains: Global 
health status, functional scales (physical, emotional, role, cognitive, social 
functioning), and symptom scales. According to the reference manual, all three 
domains were analyzed and presented as mean ± standard deviation. All three domains 
measure range in score from 0 to 100. A high score of global health status and a high 
score for the functional scale, indicate a high QoL and a healthy functioning, 
respectively. In contrast, a high score for the symptom scale, indicates a high level of 
symptomatology (63). 
Other relevant clinical characteristics i.e. age, gender, etiology, diabetes status, use of 
opioids were obtained from the patient medical record.  
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4.4.2 OBJECTIVE ASSESMENTS 
  
A detailed description of the three MRI techniques used in study I and study II, will 
be elucidated in this section. Please refer to Paper I-IV, for more technical information 
regarding sequence settings for each MRI technique.  
4.4.2.1 STRUCTURAL MRI 
 
T1-weigted images are the most commonly collected structural images, providing a 
basic anatomical image of the cerebrum (51). Using T1-images, voxel-based 
morphometry analyses (VBM) can be performed to assess the gray matter volume  
and surface-based morphometry analyses (SBM) to investigate the cortical thickness 
(12,65). In brief VBM technique uses statistical analysis approach to characterize 
changes in brain anatomy among subjects, enabling to study the presence of atrophy 
(66). Data preprocessing is an essential part of the MRI analysis. Preprocessing occurs 
before conducting the statistical analyses (67). The rationale behind preprocessing is 
a) to diminish the influence of data acquisition and physiological artifacts, b) to check 
statistical assumptions as well as transforming the data to meet these assumptions, and 
finally c) to standardize the location of brain regions across subjects to achieve 
validity and sensitivity in group analysis (67).  
When working with T1 images, the preprocessing pipeline consists of segmentation 
(identifying gray, white matter and cerebro-spinal fluid), normalization (image 
transformation into a standard anatomical reference space using DARTEL), 
modulation (involving scaling by the amount of contraction, meaning that the 
modulated gray matter remains the same as it would be in the original volumes), and 
finally spatial smoothing (blurring anatomical differences as well as meet the 
assumption of random field of theory) (67) (Figure 4). After, preprocessing, the 
statistical analysis will be performed in order to assess the group differences. The 
statistical analysis will be described later (section 4.5).  
4.4.2.2 FUNCTIONAL MRI 
 
Similar to the structural image, the very first step in fMRI data analysis is 
preprocessing (67,68). In order to perform the preprocessing of the fMRI data, both 
the T1 structural scan and gradient EPI scan (fMRI) are required. The first step in 
preprocessing is slice-timing (67). Normally, fMRI data is acquired in slice-wise 
manner, meaning that some slices are collected later than other. Hence, the voxels do 
not have the same time points (67). Slice-timing correction enables to shift each 
voxel’s time series so that all the voxels appear to have been sampled simultaneously. 
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The second step in fMRI preprocessing is motion correction (67). When analyzing 
fMRI data, it is pre-assumed that the voxels depicts the same region of the brain at 
every time point. Conversely, if the head moves between acquisitions, the voxels’ 
signal intensity becomes “contaminated” (67). Thus, motion correction will be 
performed to compensate for the subjects’ head movement by rotating and translating 
each individual image. The third step is co-registration, in which the high resolution 
3D T1 image is aligned with the functional images (67). Finally, segmentation, 
normalization and smoothing are performed as part of the preprocessing, which will 
be performed identical to the structural image preprocessing (Figure 4) (67). After 
completion of preprocessing, the statistical group analyses will be performed (section 
4.5), which will be described later.   
4.4.2.3 MR SPECTROSCOPY 
 
MR spectroscopy provides information about metabolic process in the brain and is 
widely used in the clinic and in research (52). Even though MR spectra can be 
obtained from other nuclei, 1H protons is the most used, due to the high sensitivity 
and abundance. Hence, the basic principles behind this technique is based on proton 
nuclear MR spectroscopy (1H-NMR) (69). In the conventional MR images, we are 
mainly interested in the signal from 1H to H2O. For MR spectroscopy, we are not 
interested in the signal processing of 1H to H2O, in contrast we are only interested in 
the signal from 1H to the other than H2O molecules i.e. glutamate and N-acetyl-
aspartate (69).  
In brief, 1H-NMR, which is most commonly known as MR spectroscopy, require 
standard radio frequency coils and a software package to analyze the brain metabolite 
concentrations (69). The spectra consists of a collection of peaks with different 
resonance frequency (chemical shift). In this Ph.D. study, MR spectroscopy were 
acquired using PRESS sequence from four different brain regions (for more details 
see Paper III) (70). The locations of those regions were placed with anatomical 
guidance from T1 and T2 structural scans. The collected data were then analyzed in 
the software package LCModel in which water scaling and eddy-current correction 
was conducted (Figure 4) (71). Next, the data were quality checked based on signal-
to-noise ratio and full width at half maximum. Finally, statistical group analyses were 
performed on the selected brain metabolites.  
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 Figure 4: Overview of the MRI data analysis. Three different MRI data were acquired. 
Structural MRI was used to assess gray matter volume alterations using CAT12 toolbox. MR 
spectroscopy was used to assess brain metabolites alterations using LC model. Functional MRI 
was used to assess brain networks changes using CONN toolbox.  
4.5 STATISTICAL ANALYSIS 
  
Several analyses methods were used in study I and study II, depending on the study 
design, data construction and aims. 
In study I, the MRI data were analyzed using unpaired 2-sample test for baseline data, 
while repeated measures analysis of variance (RM-ANOVA) was performed to assess 
the longitudinal changes for both healthy controls and CP patients. The clinical data 
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were analyzed using 2-sample t-tests, or 2-sample Wilcoxon rank sum test to detect 
difference between the groups. Furthermore, correlations tests were conducted using 
Person or Spearman’s as appropriate in order to assess any association between MRI 
data and clinical data.  
In study II, unpaired 2 sample test was performed to analyze MRI data and clinical 
data to detect differences between the groups (CP patients and healthy controls). 
Furthermore, both multiple regressions models and correlation analysis (Person or 
Spearman’s) were performed to assess any association between MRI data and clinical 
data. Detailed descriptions of the statistical analysis is described in Papers I-IV.  
Given that the studies could be considered as explorative studies, it is challenging to 
estimate the sample size. However, based on previous neuroimaging studies with 
structural, functional and metabolic MRI data as the primary outcomes, 12-30 patients 
seems to be sufficient to show relevant brain changes (9,68,72).The sample size of 
study I is 23 CP patients and 14 healthy controls. For study II the sample size was 35 
CP patients and 23 healthy controls. Due to drop-outs and poor data quality, Paper II, 
III, and IV have different sample size. A detailed explanation for different sample 
sizes is explained in Table 2. P values less than 0.05 was considered statistical 
significant.  
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Table 2: Overview of the sample size in study I and study II. Abbreviations: CP: chronic 
pancreatitis. fMRI: functional magnetic resonance imaging.  
  
Study Paper Sample size Explanation 
I I Baseline: 23 CP patients and 
14 healthy controls were 
scanned and analyzed.  
Follow-up: 11 CP patients 
and 12 healthy controls were 
scanned and analyzed. 
Drop-out patients (n=12)  
- Continued excessive alcohol 
drinking (n = 2) 
- Declined to participate (n = 4) 
- Dead (n = 3) 
- Moved to a new place (n = 3) 
 
Drop-out controls (n=2):  
-Breast cancer (n = 1) 
-Knee pain (n = 1) 
II II 35 patients were scanned. 
However only 33 patients 
were in included in the 
analysis. 23 healthy controls 
were scanned and analyzed.  
2 patients were excluded due to 
poor data quality. 
II III 35 patients were scanned. 
However only 31 patients 
were included in the 
analysis. 23 healthy controls 
were scanned and analyzed.  
In addition to the two patients 
with poor data quality, two 
patients were further excluded 
due to ethanol peaks in the 
metabolite spectra. In total four 
patients were excluded in Paper 
III. 
II IV 35 patients were scanned. 
However only 30 patients 
were included in the 
analysis. 23 healthy controls 
were scanned and analyzed.  
In addition to the above four 
patients, a patient with poor 
fMRI data was excluded. In total 
five patients were excluded in 
Paper IV.  
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CHAPTER 5. RESULTS 
 
The key results from the studies are presented in this chapter. Mores detailed results 
are reported in Papers I-IV. An overview of the main results from Papers I-IV is 
illustrated in Figure 5.  
5.1. AIM I 
 
Aim I: To investigate changes in the brain structure over time using structural MRI in 
painful CP patients compared with controls (Paper I) and potential associations to pain 
related symptoms (Paper I) and to explore associations between morphological brain 
changes and disease characteristics and risk factors (Paper II). 
 
Key results:  
• Accelerated total gray matter volume decrease (P = 0.010) and pronounced 
gray matter volume loss in precentral gyrus (P = 0.021) and putamen (P = 
0.035) in CP patients compared to healthy controls during the 7-year follow-
up (Paper I). 
• Increase in pain scores over 7-years was associated with a less reduction of 
thalamic gray matter volume (r = 0.61, P = 0.046), (Paper I). 
• Reduced gray matter volume and cortical thickness in CP patients compared 
with healthy control (P < 0.05), (Paper II). 
• Alcoholic etiology of CP was independently associated with a decreased 
total gray matter volume (P < 0.001), whereas no association was observed 
for pain or other disease characteristics (all P > 0.05) (Paper II). 
Interpretation: Our findings implicate that longstanding pain in CP results in 
measurable macrostructural morphological alterations over time within specific areas 
of the brain involved in processing and integration of the sensory system (Paper I). 
Compared with healthy controls, patients had reduced gray matter volume and cortical 
thickness with no associations to pain symptoms, likely because of the effects of 
previous alcohol use, which might obscure brain changes caused by pain (Paper II). 
The longitudinal study provides further evidence, supporting the hypotheses that the 
central pain processing is abnormal in CP while the cross-sectional study indicates 
that alcoholic etiology is the most prominent contributing factor for structural brain 
alterations in CP patients.  
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5.2 AIM II 
 
Aim II: To assess brain metabolites using MR spectroscopy in CP patients, compared 
with healthy controls, in pain related areas (ACC, insula and prefrontal cortex) and in 
a parietal control region, as well as to compare brain metabolite levels in subgroups 
with different disease characteristics including pain (Paper III). 
 
Key results:  
• CP patients had increased glutamate/creatine level in the ACC (P = 0.045) 
and reduced N-acetylasparate/creatine levels in the parietal region (P = 
0.027) compared with healthy controls.  
• Patients with highest score of pain had higher glutamate/creatine level in 
the ACC compared to patients with lowest pain scores (P = 0.039). 
• Lower parietal N-acetylasparate/creatine level was found in patients with 
alcoholic etiology as compared to patients without alcoholic etiology and 
healthy controls (P < 0.006).  
 
Interpretation: Alterations in neurotransmitters have been demonstrated in CP 
patients, which is further associated to pain and alcoholic etiology. Findings from this 
study indicates that CP patients have neurochemical disturbance in addition to 
structural reorganization, which may likely be explained by nociceptive effect and 
neurotoxic effect. Overall imbalance of neurotransmitters in CP patients may be 
indicator of neuronal dysfunction.  
 
5.3 AIM III 
 
Aim III: To assess the resting state networks (default mode (DMN) and salience mode 
networks (SN)) using functional MRI in CP patients compared with healthy controls, 
and to explore the association between altered brain network connectivity and the 
clinical parameters as well as brain metabolites (Paper IV).  
 
Key results:  
• CP patients showed predominantly hyper-connectivity in both DMN and SN 
compared to healthy controls (P < 0.05). 
• CP patients had significantly reduced anti-correlated functional connectivity 
between DMN and SN compared to healthy controls (all P ≤ 0.009). 
• The altered DMN connectivity in CP correlated to the brain metabolite 
glutamate/creatine level in ACC (r = 0.363, P = 0.048). 
 
41 
• There were no associations between altered functional connectivity and the 
disease characteristics such as QoL or pain symptoms.  
Interpretation: The function of the DMN and SN are abnormal in CP patients 
compared with healthy controls. Altered DMN was further associated with the 
neurotransmitter glutamate/creatine level, indicating that glutamate may modulate 
DMN and an imbalance of glutamate may hinder deactivation of DMN. Lack of 
deactivation of DMN may consequently result in an abnormal anti-correlation 
between DMN and SN. Taken together, our findings share similarities with other 
chronic pain conditions, and support our understanding of altered brain circuitry 
associated with the CP disease and pain development. 
 
Figure 5: Overview of the main results from Paper I-IV. Abbreviations: CP: chronic 
pancreatitis. MR: magnetic resonance. MRI: magnetic resonance imaging. GMV: gray matter 
volume. Glu/cre: glutamate/creatine level. NAA/cre: N-acetyl-aspartate/creatine. ↑: 
increased. ↓: decreased. DMN: default mode network. SN: salience network.  
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CHAPTER 6. DISCUSSION 
Multimodal MRI techniques were used to assess brain changes in CP patients 
compared with healthy controls. Two different clinical studies were conducted: a 
longitudinal study (study I), and a cross-sectional study (study II), to assess the brain 
changes with three different MRI modalities (structural MRI, MR spectroscopy, and 
fMRI). Those three MRI modalities provided anatomical, physiological, and chemical 
information of the brain. Overall, our findings provide strong evidence of structural, 
functional and metabolic alterations in CP patients. These alterations seem related and 
partly associated with both the patient reported pain, but also other disease 
characteristics   such as alcoholic etiology. This section consists of three major parts. 
Firstly, the objective assessments will be discussed including structural MRI, MR-
spectroscopy, and functional MRI. Secondly, the subjective assessments will be 
discussed. Thirdly, the methodological considerations will be discussed.  
 
6.1 STRUCTURAL MRI 
  
Assessment of the brain structure with MRI provided interesting insight about 
structural cortical reorganization in CP patients. Structural cortical reorganization was 
found both in the longitudinal study (study I) (73) and cross-sectional study (study II) 
(74). Particularly, Paper I revealed that the CP pain is related to morphological brain 
alterations over time involving pain related brain regions (incl. thalamus, putamen, 
and superior temporal gyrus), reflecting that this brain plasticity may be caused by 
long-term pain inputs. Importantly, CP patients showed also a trend in accelerated 
total gray matter volume loss compared with healthy controls. The majority of 
published MRI studies are cross-sectional studies (48,68,75), assessing the current 
brain abnormalities compared with healthy controls, however, little is known about 
the temporal evolution of the altered brain structure and its association to the clinical 
characteristics in chronic pain patients, particularly in CP patients. Knowledge from 
longitudinal studies may contribute with valuable information for future intervention 
studies. 
Paper II, revealed reduced gray matter volume and cortical thinning in several brain 
areas. The altered brain morphology was further related to alcoholic etiology of CP 
and not to pain. Altered brain structure in both studies are in line with the findings 
from previous chronic pain studies. MRI studies with other chronic visceral pain 
conditions, particularly, irritable bowel syndrome (IBS) have shown reduced gray 
matter density in several brain areas such as prefrontal and posterior parietal region 
(48) as well as reduced cortical thickness (48).  
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Taken together, Paper I indicates that the structural brain alterations over time is 
associated with progression in pain, while Paper II strongly indicates that the 
structural reorganization is primarily associated with alcoholic etiology. Although the 
MRI findings overall shared similarities between the two studies, there were 
differences in the clinical association. Hence, there could plausibly raise doubt about 
the conclusion of the studies. Comparison of the two structural studies should be 
performed with caution given that the papers have different study design, different 
timeframe, and different clinical data. Paper I, studied brain changes over a 7-year 
period. For this purpose, pain diaries where collected both at the baseline visit and at 
the follow-up visit. This paper did not consider all the risk factors associated with CP. 
Paper II, was based on a cross-sectional study, assessing the current brain changes. 
Furthermore, Paper II took a major step forward into explaining the brain changes in 
CP patients, by taking several risk factors and patient outcomes into consideration 
when assessing the brain using a multivariate regression model. A limitation in the 
cross-sectional study was lack of pain diary prior to MRI scan. The pain in CP patients 
is often highly fluctuating, therefore we should have obtained data regarding the pain 
pattern using pain diary, to assess the true and more long-lasting pain, rather than 
asking the patients pain for the last 24 hours. Thus, it is not a major surprise, that the 
two structural MRI papers found two different clinical associations. Overall, both 
studies implicate that both pain and alcoholic etiology are two major contributing 
factors for brain plasticity in CP patients.   
 
6.2. MR SPECTROSCOPY 
 
The significantly higher level of glutamate/creatine level in the ACC in CP patients 
(76) may not be surprising, considering that glutamate is an excitatory 
neurotransmitter, facilitating and amplifying pain signals and is previously known to 
be increased in several chronic pain conditions (77,78). Most interestingly, we found 
that patients with highest score of pain had increased glutamate level compared with 
patients with lowest score of pain symptoms. This, confirms that CP patients with pain 
could have an imbalance of inhibitory and facilitatory descending pain modulation, 
resulting in greater gain of incoming nociceptive signals (19,46). However, it remains 
unclear whether an imbalance of inhibitory and facilitatory descending pain 
modulation leads to increased pain or weather increased pain leads to imbalance of 
inhibitory and facilitatory descending pain modulation. 
Another major finding in Paper III, was the significant reduced N-
acetylasparate/creatine levels in CP patients. Particularly, patients with alcoholic 
etiology of CP had reduced N-acetylasparatate/creatine level in parietal white matter, 
compared to patients without alcoholic etiology. Interestingly, the decrease did not 
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occur in pain related areas, but in the white matter parietal region consisting of myelin 
surrounded nerve fibers. N-acetylasparate/creatine is known to be a marker for the 
neuronal functionality and density (79), thus a decrease of N-acetylasparate/creatine 
implicates that previous alcohol abuse might be a significant factor contributing 
damage of neural structure and organization. Our findings are consistent with previous 
studies, demonstrating that alcohol is associated with white matter demyelination as 
well as degeneration (80). Taken together, we demonstrated that altered brain 
metabolites were both strongly associated to pain and to alcoholic etiology, however 
the results should be interpreted with caution, as the sample size of the subgroup 
analyses were relatively small.  
 
6.3. FUNCTIONAL RESTING STATE MRI 
 
Functional MRI was chosen to assess the resting state functional connectivity changes 
in CP patients in the two important brain networks: default mode network and salience 
network. Those networks have been shown to be altered in several chronic pain 
conditions i.e. fibromyalgia, migraine, and chronic lower back patients (72,81,82).  
 
Based on Paper IV, we found that CP patients had hyper-connectivity within default 
mode network and salience network. Normally, the default mode network is highly 
activated during rest and deactivated while performing a task or in the presence of 
pain (83). In contrast to our hypothesis, we found that these patients have hyper-
connectivity during rest compared to healthy controls.  
Another prominent finding in the study was reduced anti-correlation between default 
mode network and salience network, which was not correlated to pain scores or 
alcoholic etiology. The reduced anti-correlation between those networks could be due 
to abnormal default mode network connectivity in CP patients. Abnormal anti-
correlation between default mode network and salience network has previously been 
demonstrated in chronic pain patients (82,84) (incl. migraine patients (68), and 
fibromyalgia patients (85),), implicating functional damage. This abnormal anti-
correlation has not only been demonstrated in chronic pain conditions, but also in 
several brain disorders such as in Alzheimer’s disease suggesting that chronic pain 
share similarities with several brain disorders (84), and provides evidence that altered 
anti-correlation between default mode network and salience network may be related 
to altered attention. However, this need to be investigated further i.e. by conducting a 
cognitive MRI study to assess the attention in CP patients. 
 
Moreover, we showed that increased connectivity in default mode network was 
associated to increased level of ACC glutamate/creatine in CP patients. Association 
46
 
between default mode network and glutamate has previously been demonstrated by 
Hu et al 2013, suggesting that glutamate levels modulate brain activation (86). 
Particularly the excitatory neurotransmitter glutamate is thought to prevent 
deactivation of the default mode network (86). This, may explain the hyper-
connectivity of default mode network in CP patients. By combining fMRI and MR 
spectroscopy, Paper IV has shown evidence of neurochemical characteristics that 
could affect the function of the default mode network, potentially providing novel 
insight into the function of default mode network in CP patients. Although, Paper IV 
failed to show an association between pain scores and brain connectivity. The results 
strongly implicate that the patients exhibit functional reorganization probably due to 
imbalance of excitatory neurotransmitter in glutamate, which primarily appears in CP 
patients with pain (Figure 6).  
 
 
Figure 6: Potential mechanisms of glutamate involvement in default mode network. 
Abbreviations: CP: chronic pancreatitis. DMN: default mode network. SN: salience network.  
 
6.4. BRAIN CHANGES AND ITS ASSOCIATION TO CHRONIC 
PAIN AND ALCOHOL 
 
Previous EEG and QST studies have shown abnormal pain processing in the CP 
patients (5,27). None of those studies have directly considered disease characteristics 
in the data analysis, such as etiology, use of opioids, diabetes, and disease duration. 
Addressing these disease characteristics is crucial, as each factor is known to 
potentially affect the brain (70).  
Overall, the four papers implicate that the brain changes are associated to both pain 
and alcoholic etiology (Figure 7). Differentiating of whether the brain changes are 
associated with chronic pain or alcoholic etiology can be challenging, as they are 
likely a complex combination of both. Thus, structural, functional and metabolites 
brain changes may be both due to a combination of alcoholic etiology, which is the 
most prevalent cause for development of CP, and long-lasting pain which is the most 
severe clinical manifestation of CP. 
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Figure 7: Paper I, III and IV provide structural, metabolic and functional brain alterations 
related to pain in chronic pancreatitis patients, while Paper II and III provide evidence of 
structural and metabolic brain alteration in relation to alcoholic etiology. Overall, Paper I-IV, 
implicate that brain alterations may be caused by a combination of both nociceptive and 
neurotoxic effect. 
 
 
Lack of associations between pain and altered brain morphology in Paper II may differ 
likely due to the fact that pain in CP patients is often highly fluctuating and that the 
reported pain at the time of MRI scan does not exactly reflect the long-lasting pain 
input to the brain. Furthermore, as a results of external inputs, chronic pain patients 
have an altered internal milieu, and/or altered endogenous processing (47). Examples 
of external inputs in CP patients could be risk factors associated with the disease 
(87,88) i.e. alcohol abuse for a long period, nicotine consumption, hyperlipidemia, 
etc. In addition to risk factors, external inputs could also be extensive use of opioids, 
psychological problems, social factors, and depression, and diabetes (Figure 8). Both 
in Paper I and II, diabetes were taken into consideration in the MRI analysis, as 
previous studies have shown that diabetes may alter brain structure, function (89) and 
metabolites (90). Based on multiple regression model, Paper II showed that diabetes 
had no association to gray matter volume loss in CP patients.  
 
Alcohol abuse remains the most prevalent risk factor for the development of CP and 
may likely play an essential role in the brain alterations in CP patients. For instance, 
if the patients have had many years of previous alcohol abuse and only experienced 
pain the last few months, then previous alcohol abuse may obscure the brain changes 
related to pain. Thus, not only nociceptive inputs play an essential role in the structural 
and functional reorganization, but previous neurotoxic inputs play equally an effect 
on the brain, both anatomically and chemically, referring to Paper II and Paper III 
(Figure 7). To identify the unique brain changes related to alcoholic etiology (and 
other potential factors influencing the brain), future studies should ideally recruit a 
Pain
Paper I
(Strucutral MRI)
Paper III
(MR spectroscopy)
Paper IV
(fMRI)
Alcoholic etiology
Paper II
(Structural MRI)
Paper III 
(MR spectroscopy)
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new control group, for instance subjects with extensive alcohol use but without a CP 
diagnosis. To study the brain changes related to pain, future studies need to recruit CP 
patients who had never experienced abdominal pain, which is practically very 
difficult. Furthermore, given that, it is complicated to detect a clear association 
between pain and brain alterations, future CP studies should include biological (pain 
(56), medication), psychological (anxiety, depression (91), sleep) and social (alcohol 
(92), trauma (47)) data when assessing the structural brain, as those factors a known 
to affect the brain structure (Figure 8). 
 
6.5. SUBJECTIVE ASSESSMENT OF PAIN  
  
In study I, pain diary and BPI questionnaire were assessed in CP patients, showing no 
significant differences between baseline and follow-up visit. No significant difference 
between those visits, does not necessarily mean that pain pattern has been stable 
during the 7-years, due to the fact that we did not measure the pain between baseline 
visit and follow-up visit. Another major limitation in this study was that we did not 
collect clinical data during the study period, such as medication, lifestyle changes i.e. 
alcohol consumption, psychological status i.e. depression (Figure 8) which are known 
also to affect the brain structure. Lack of controlling for those confounders between 
the two visits, generates a “black box” of factors that could contribute to alterations 
of the brain. Therefore, it can be fundamentally challenging to assess whether the 
altered brain morphology solely is associated to the effect of long-lasting pain. Future 
longitudinal studies are strongly recommended to repeatedly and systematically 
obtain physiological, psychological and social data during the entire study period. 
 
In study II, BPI and QoL data were collected for all patients to subjectively assess the 
pain and QoL in CP patients. To date, there are no ideal objective pain assessment 
tools to assess pain given that pain is a subjective response, however it would have 
been optimal to have included QST, in order to assess nociceptive activity (93). QST 
provides physiological information of the underlying pain mechanisms involving 
different modalities such as thermal, mechanical, chemical and electrical compounds. 
Association of such QST data with MRI findings, could potentially been more 
informative than only correlating MRI findings with questionnaires.  
 
Based on other chronic pain conditions, it is known that the longer the pain persists 
and the stronger it is, the more difficult is it to treat the pain, as the ongoing and long-
lasting pain is an important driver for development of central sensitization (41). 
Therefore, the first step in treating pain could be examination and profiling the sensory 
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system in CP patients, enabling the clinicians to provide a more precise and effective 
(personalized) treatment based on the central pain mechanisms (41).  
 
 
Figure 8: Several factors may affect the brain structure. The confounding factors could be 
biological (pain fluctuations), psychological (depression, anxiety) and social (lifestyle – 
alcohol/nicotine use, trauma etc.).  
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6.6. LIMITATIONS  
 
For study I, the sample size was relatively small and moreover there was a large drop-
out rate (52% of the patients and 14% of the healthy controls). The drop-out reasons 
are described in Paper I. Due to the fact that half of the patients discontinued, this may 
potentially have affected the MRI results, as these patients could have been those 
where regional brain atrophy and cortical thinning progressed the most, resulting in 
selection bias. Another limitation in this study was, that our sample of CP patients 
was clinical heterogeneous, meaning that the patients had different pain pattern 
(intermittent pain, constant pain, and constant pain with exacerbation). This indicates 
that the pain progression is individual and that there is a high chance of inter-subject 
variability in the general response to CP pain. For study II, lack of comprehensive 
data of the patient’s previous alcohol abuse was a limitation, as only categorical data 
were obtained (whether the patients had alcoholic etiology or not). Thus, to assess the 
effect of alcoholic etiology, more data is needed such as years of alcohol abuse, 
amount of alcohol intake, etc. Also, Study II, was a cross-sectional study, hence, it 
was not possible to determine the true causal relationship between cerebral 
abnormalities and the disease characteristics.  
Both study I and study II share some common limitations. Firstly, CP patients used 
medication i.e. opioids. Secondly, the pain was only assessed through clinical 
questionnaires. Future studies should include QST to better assess the underlying 
changes in the sensory system in CP patients. In regards to clinical data, futures studies 
should collect the clinical data more systematically. For instance in the longitudinal 
study, only baseline and follow-up data were collected, which resulted in generation 
of “black box”, not knowing what that patients is going through during the 7 years. 
Also, both study I and study II, did not include exocrine insufficiency data. Those data 
would be valuable when assessing the brain in CP patients. 
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CHAPTER 7. CONCLUSION 
 
This Ph.D. thesis had an overall objective, divided into three aims.  
In conclusion, we have demonstrated that, CP patients after a 7-year follow-up period 
had accelerated gray matter volume loss and cortical thinning, particularly in the pain 
related areas. The altered brain structure was associated with progression in pain 
score. Reduced gray matter volume and cortical thinning in CP patients were further 
confirmed by the cross-sectional study. Although, the latter study found alterations in 
the pain related brain regions, no associations were found to the pain. Interestingly, 
we demonstrated that alcoholic etiology is the most prominent risk factor associated 
with altered brain morphology in CP patients. Taken all together, the structural MRI 
technique showed long-term structural reorganization with involvement of both 
nociceptive effect and previous neurotoxic effect on the brain (aim I).  
Demonstration of potentially both alcoholic neurotoxic effects and long-lasting 
nociceptive effects on the brain in CP patients was further confirmed by the MR 
spectroscopy study. This technique detected reduced parietal N-
acetylasparate/creatine in CP patients with alcoholic etiology, and increased ACC 
glutamate/creatine level in CP patients with highest level of pain compared with CP 
patients with lowest level of pain (aim II). Finally, functional reorganization was 
demonstrated using the resting state fMRI technique. Particularly, this technique 
showed hyper-connectivity within the default mode network and salience network, as 
well as reduced anti-correlation between those two networks. Most, importantly, we 
found an association between altered glutamate level (MR spectroscopy) and altered 
default mode network (fMRI), suggesting that glutamate may be involved in 
modulation of brain function such as the default mode network. Altogether, the fMRI 
study implicates that the CP patients have disrupted communication between the 
networks, similar to other chronic painful disorders, which may be potentially 
influenced by altered glutamate level (aim III). 
 
To date, CNS abnormalities associated with pain has been receiving increased 
attention. However, this Ph.D. thesis, provides evidence showing that the pain 
(nociceptive effect) is not the only modulator for CNS abnormalities in CP patients, 
but a combination of both pain and previous alcohol use (neurotoxic effect) result in 
complex CNS abnormalities. This has been demonstrated using a multimodal MRI 
approach including structural, functional and metabolic assessment of the brain.  
Structural, functional and neurochemical abnormalities of the brain may be reversed 
upon successful resolution of pain (94,95) and in combination with cessation of 
alcohol.  
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CHAPTER 8. CLINICAL 
IMPLICATIONS AND FUTURE 
PERSPECTIVES 
 
The results from this Ph.D. project has improved our understanding of CNS 
abnormalities in CP patients, demonstrating that the CNS changes is not solely driven 
by long-lasting nociceptive inputs, but it is most likely a complex combination of 
ongoing nociceptive and neurotoxic effects (i.e. alcohol) affecting the brain. 
Therefore, future studies should aim to distinguish between those effects.  
To date, changes in the pancreatic morphology has received a lot of attention, resulting 
in invasive treatments (incl. endoscopic pancreatic duct clearance, pancreatic duct 
stenting and surgery). The rationale for such treatments is that decreasing the ductal 
pressure or resecting an inflammatory pancreas mass will lead to pain reduction (31). 
However, the pain has often a neuropathic origin involving central sensitization, 
structural and function reorganization and neurochemical alterations, hence invasive 
treatment would not always be efficient. In this case, new treatments with less side-
effects targeting the CNS are highly warranted.  
One such option is a treatment with transcutaneous vagal nerve stimulation (t-VNS). 
T-VNS has been shown to have an analgesic effect as well as anti-inflammatory effect, 
even though the exact mechanisms by which t-VNS modulates pain is unclear. T-VNS 
treatment is FDA approved for the acute treatment of migraine patients (96). Based 
on this rationale, a randomized, double blind, sham-controlled, cross-over, controlled 
study has recently been conducted by our research group (97). The protocol is 
published in BMJ Open, and registered at Clinicaltrials.gov with following number: 
NCT03357029. This study was conducted to investigate the analgesic effect a two-
week t-VNS treatment in CP patients, as well as to explore the mechanisms of the 
anti-nociceptive effect using advanced neuroimaging techniques, QST, clinical 
questionnaires, pain diary, collection of blood samples and by measuring cardiac 
vagal tone. Among others the main efficacy parameters to be assessed are clinical pain 
relief and induced brain alterations using MRI. The data has not been analyzed yet.  
Moreover, future studies should also assess microstructural white matter changes 
using diffusion tensor imaging (DTI). Although, the DTI was collected in both study 
I and study II, DTI data was not analyzed due to technical issues and due to limited 
time. Based on structural MRI, functional MRI, MRI spectroscopy and DTI, future 
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studies should attempt to conduct multivariate pattern analysis combining information 
from all of the four techniques to understand the complex CP disease effects across 
the brain.  
Given that there are no objective assessments for pain, monitoring progress with 
structural, functional and metabolic scans, may help measure changes in patients with 
pain, in addition to QST. The latter enables to characterize the pain profile and 
identifying relevant pain mechanisms in CP patients with pain. In the same way, 
structural scans may contribute with information on cortical thickness and volume 
loss (73,74,98). Metabolic scans enables to detect alterations in several 
neurotransmitters as a results of treatment (99,100). Functional scan facilitates to 
define some objective outcomes such as sustained central sensitization or responses 
to specific analgesia (53,54). Future clinical trials are highly recommended to include 
MRI techniques to assess the effect of a treatment on the brain.   
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